April 2017
Is the STAT-Dx the next big thing after BioFire ?
27/04/17 17:26
PHOTO (ECCMID 2017)VIENNA (GenomeWeb) – Spain's Stat-Dx this week unveiled the first production units of its fully integrated and automated molecular testing platform for infectious diseases along with the system's first test cartridge, a respiratory panel designed to detect and identify up to 22 viral and bacterial pathogens simultaneously. Barcelona-based Stat-Dx (formerly Stat-Diagnostica) also plans to begin clinical trials of the platform and respiratory panel over the next few months at various hospitals across Europe with the intent of launching the products with CE marking in the second half of this year…
Read More…
Hig-multiplex race for EUROPE: Syndromic microbiology
21/04/17 12:39
Who knows me professionally knows what I think about BioMeriuex as the company, but what we all need to acknowledge is that the BioFire was the right move for BioMeriuex.
What is about new players on the market? Is GenMark coming close? GenMark showed very little marketing presence in the Europe, but they sold their first system and I consider them as the serious competitor to BioFire. The only disadvantage of the system is complicated microfluidics in the cartridge. BioFire cartage looks much more simple and hopefully has a potential of getting cheaper (under 90 EUR / test).
A sample in, an answer out is the idea behind high multiplex products. The reality is quite opposite. This kind of testing on different platforms bring as well lots of frustration ones when you see your test report. The main reason for the frustrations are analytes that cannot be reported (terminology: unreported) due to the auto-fluorescence or some other problem, in particular, are of the test.
Last week I had a very interesting case. The patient came to form Africa with the high fiver, was positive for malaria tropica with ca. 10% infected erythrocytes seen in the blood-smear. Because of diagnosis of severe malaria tropica, the patient was hospitalized in the ICU. One of the leading symptoms was diarrhea that could be easily connected to the clinical presentation of complicated malaria tropica. Good medical practice is always to exclude an infective cause of the symptoms of diarrhea and because of that, the stool sample was tested in the BioFire that reported Norovirus, EPEC, and EAEC in the stool. In any case, the result was the reason enough to isolate the patient. Is it possible to distinguished which pathogen is causing the symptoms in the syndromic panels? When are we going to see the second generation of the syndromic tests that are going to be able to address this question as well?
What is about new players on the market? Is GenMark coming close? GenMark showed very little marketing presence in the Europe, but they sold their first system and I consider them as the serious competitor to BioFire. The only disadvantage of the system is complicated microfluidics in the cartridge. BioFire cartage looks much more simple and hopefully has a potential of getting cheaper (under 90 EUR / test).
A sample in, an answer out is the idea behind high multiplex products. The reality is quite opposite. This kind of testing on different platforms bring as well lots of frustration ones when you see your test report. The main reason for the frustrations are analytes that cannot be reported (terminology: unreported) due to the auto-fluorescence or some other problem, in particular, are of the test.
Last week I had a very interesting case. The patient came to form Africa with the high fiver, was positive for malaria tropica with ca. 10% infected erythrocytes seen in the blood-smear. Because of diagnosis of severe malaria tropica, the patient was hospitalized in the ICU. One of the leading symptoms was diarrhea that could be easily connected to the clinical presentation of complicated malaria tropica. Good medical practice is always to exclude an infective cause of the symptoms of diarrhea and because of that, the stool sample was tested in the BioFire that reported Norovirus, EPEC, and EAEC in the stool. In any case, the result was the reason enough to isolate the patient. Is it possible to distinguished which pathogen is causing the symptoms in the syndromic panels? When are we going to see the second generation of the syndromic tests that are going to be able to address this question as well?
POSTER - ECCMID 2017: Single-Cell MALDI-TOF based diagnostics
02/04/17 22:32
We are happy to present our posters at ECCMID 2017. Single-Cell MALDI-TOF based diagnostics of prosthetic joint infections.
We invested lost of time in the optimising the sample-prep for MALD-TOF and PCR based analysis. By going directly from the samples we are not just able to detect the microorganisms but the hallmarks of innate immune response as well. We are very excited in further development of our project.
***
ECCMID_2017 PDF Poster
We invested lost of time in the optimising the sample-prep for MALD-TOF and PCR based analysis. By going directly from the samples we are not just able to detect the microorganisms but the hallmarks of innate immune response as well. We are very excited in further development of our project.
***
ECCMID_2017 PDF Poster
